Literature DB >> 17572702

Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.

M T Le1, M K Pugsley, G Vauquelin, I Van Liefde.   

Abstract

BACKGROUND AND
PURPOSE: Whereas some angiotensin II (Ang II) type 1 receptor blockers (ARBs) produce surmountable antagonism of AT(1) receptors, others such as olmesartan and telmisartan display varying degrees of insurmountability. This study compared the molecular interactions of olmesartan and telmisartan with the human AT(1) receptor, using well characterised in vitro methods and model systems. EXPERIMENTAL APPROACH: CHO-K1 cells that stably express human AT(1) receptors (CHO-hAT(1) cells) were used in several pharmacological studies of olmesartan and telmisartan, including direct radioligand binding and inhibition of Ang II-induced inositol phosphate (IP) accumulation. KEY
RESULTS: Both ARBs were found to be competitive antagonists that displayed high affinity, slow dissociation, and a high degree of insurmountability for the AT(1) receptor (the latter greater with olmesartan). Their receptor interactions could be described by a two-step process with the initial formation of a loose complex (IR) and subsequent transformation into a tight binding complex (IR*). In washout experiments, [(3)H] telmisartan dissociated from the receptor with a half-life of 29 min and the Ang II-mediated IP accumulation response was 50% maximally restored within 24 min, whereas values for [(3)H] olmesartan were 72 min and 76 min, respectively. CONCLUSIONS AND IMPLICATIONS: The high degree of insurmountability, slow dissociation, and high affinity of olmesartan for its receptor may relate to its ability to stabilise IR* via the carboxyl group of its imidazole core. In comparison, telmisartan displays a less potent interaction with the receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17572702      PMCID: PMC2042929          DOI: 10.1038/sj.bjp.0707323

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.

Authors:  F L Fierens; P M Vanderheyden; J P De Backer; G Vauquelin
Journal:  Eur J Pharmacol       Date:  1999-05-14       Impact factor: 4.432

2.  Historical evolution of angiotensin II receptor blockers: therapeutic advantages.

Authors:  H Gavras
Journal:  J Am Soc Nephrol       Date:  1999-04       Impact factor: 10.121

3.  Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition?

Authors:  P M Vanderheyden; F L Fierens; G Vauquelin
Journal:  Biochem Pharmacol       Date:  2000-12-01       Impact factor: 5.858

Review 4.  Pharmacological properties of angiotensin II receptor antagonists.

Authors:  P B Timmermans
Journal:  Can J Cardiol       Date:  1999-11       Impact factor: 5.223

5.  Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.

Authors:  P M Vanderheyden; F L Fierens; J P De Backer; N Fraeyman; G Vauquelin
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

Review 6.  International union of pharmacology. XXIII. The angiotensin II receptors.

Authors:  M de Gasparo; K J Catt; T Inagami; J W Wright; T Unger
Journal:  Pharmacol Rev       Date:  2000-09       Impact factor: 25.468

Review 7.  Newly emerging pharmacologic differences in angiotensin II receptor blockers.

Authors:  S Oparil
Journal:  Am J Hypertens       Date:  2000-01       Impact factor: 2.689

8.  Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells.

Authors:  F Fierens; P M Vanderheyden; J P De Backer; G Vauquelin
Journal:  Eur J Pharmacol       Date:  1999-02-19       Impact factor: 4.432

9.  Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors.

Authors:  P M Vanderheyden; F L Fierens; J De Backer; G Vauquelin
Journal:  Biochem Pharmacol       Date:  2000-04-15       Impact factor: 5.858

10.  A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.

Authors:  G Vauquelin; P Morsing; F L Fierens; J P De Backer; P M Vanderheyden
Journal:  Biochem Pharmacol       Date:  2001-02-01       Impact factor: 5.858

View more
  24 in total

Review 1.  Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays.

Authors:  Steven J Charlton; Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 3.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

Review 4.  Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Authors:  Georges Vauquelin
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

5.  The non-biphenyl-tetrazole angiotensin AT1 receptor antagonist eprosartan is a unique and robust inverse agonist of the active state of the AT1 receptor.

Authors:  Takanobu Takezako; Hamiyet Unal; Sadashiva S Karnik; Koichi Node
Journal:  Br J Pharmacol       Date:  2018-05-06       Impact factor: 8.739

Review 6.  Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.

Authors:  Wijnand J C van der Velden; Laura H Heitman; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

7.  Do all angiotensin II type 1 receptor blockers have the same beneficial effects?

Authors:  S Miura; K Saku
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

8.  Angiotensin II receptor type 1--a novel target for preventing neonatal meningitis in mice by Escherichia coli K1.

Authors:  Subramanian Krishnan; Muthusamy V Shanmuganathan; Douglas Behenna; Brian M Stoltz; Nemani V Prasadarao
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

9.  Synthetic nanobodies as angiotensin receptor blockers.

Authors:  Conor McMahon; Dean P Staus; Laura M Wingler; Jialu Wang; Meredith A Skiba; Matthias Elgeti; Wayne L Hubbell; Howard A Rockman; Andrew C Kruse; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-04       Impact factor: 11.205

Review 10.  Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease.

Authors:  Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.